Table of Content

1. Introduction to Tetraspecific Antibodies
1.1 Clinical Overview
1.2 History & Development


2. Tetraspecific Antibodies Mechanism of Action
2.1 Multispecific Formats
2.2 Tetraspecific Antibodies Bringing Immune Cells & Target Cells Closer


3. Tetraspecific Antibodies Clinical Trials Overview
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Indication


4. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase
4.1 Preclinical
4.2 Phase I
4.3 Phase I/II
4.4 Phase II


5. Current Clinical Development & Future Commercialization Outlook
5.1 Current Scenario
5.2 Future Market Commercialization Outlook


6. Tetraspecific Antibody Clinical Development Trend Analysis by Region
6.1 China
6.2 Europe
6.3 US


7. Tetraspecific Antibodies Proprietary Technologies By Company
7.1 Available Proprietary Platforms
7.2 Potential Proprietary Platforms


8. Tetraspecific Antibodies Therapeutic Application in Cancer
8.1 Solid Tumors
8.2 Hematological Disorders


9. Tetraspecific Antibodies Therapeutic Approaches
9.1 Tetraspecific Antibodies As Monotherapy
9.2 Tetraspecific Antibodies As Combinational Therapy
9.3 Tetraspecific Antibodies As Targeted Approach


10. Combination Stratagems for Tetraspecific Antibodies


11. Competitive Landscape
11.1 Innate Pharma
11.2 ModeX Therapeutics (OPKO Health) 11.3
11.3 Molecular Partners
11.4 OPKO Health
11.454 Ruijin Hospital
11.6 Sichuan Baili Pharmaceutical
11.7 SystImmune



List of Figures

Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 - Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage

Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells & NK Cells In Close Proximity

Figure 3-1: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2024
Figure 3-2: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2024
Figure 3-3: Global – Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2024
Figure 3-4: Global – Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2024

Figure 6-1: Sichuan Biokin Pharmaceutical – Clinical Pipeline
Figure 6-2: GNC-035 Phase I Study (NCT05160545) – Initiation & Completion Year
Figure 6-3: IPH6501 Phase I/II Study (NCT06088654) – Initiation & Completion Year
Figure 6-4: ModeX Therapeutics, an OPKO Health Company Pipeline

Figure 7-1: DARPin Platform - Molecular Partners
Figure 7-2: ANKET? Platform - Innate Pharma
Figure 7-3: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 7-4: STEALTH – ModeX Therapeutics
Figure 7-5: MSTAR – ModeX Therapeutics
Figure 7-6: Features of MSTAR
Figure 7-7: MATCH – Numab
Figure 7-8: Features of BiXAb
Figure 7-9: Zyngenia Technology Approach

Figure 8-1: GNC-039 Phase I Study (NCT04794972) – Initiation & Completion Year
Figure 8-2: MDX2001 Phase I/II Study (NCT06239194) – Initiation & Completion Year
Figure 8-3: GNC-038 Phase I/II Study (NCT05627856) – Initiation & Completion Year
Figure 8-4: GNC-038 Phase I/II Study (NCT05485753) – Initiation & Completion Years
Figure 8-5: GNC-035 Phase I/II Study (NCT06066203) – Initiation & Completion Years
Figure 8-6: GNC-035 Phase I/II Study (NCT06066203) – Initiation & Completion Years
Figure 8-7: Molecular Partners – MP0533
Figure 8-8: MP0533 Phase I/II Study (NCT05673057) – Initiation & Completion Year

Figure 9-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 9-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 9-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 9-4: IPH6501 - Tetra-Specific NK Cell Engager
Figure 9-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 9-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 9-7: Novel Tetraspecific Format Developed By The Roche Pharma Research & Early Development

Figure 10-1: Tetraspecific Antibody Combinations

List of Tables

Table 6-1: China – Ongoing Tetraspecific Antibody Clinical Trials

Table 9-2: GNC-038– Ongoing Clinical Trial for Hematological Cancers

Table 9-1: Monotherapy Clinical Trials For Tetraspecific Antibodies